five

Table 1_Reevaluating anticoagulation therapy for sepsis-associated disseminated intravascular coagulation based on endothelial glycocalyx shedding quantification: a single-center, retrospective, observational pilot study.docx

收藏
NIAID Data Ecosystem2026-05-02 收录
下载链接:
https://figshare.com/articles/dataset/Table_1_Reevaluating_anticoagulation_therapy_for_sepsis-associated_disseminated_intravascular_coagulation_based_on_endothelial_glycocalyx_shedding_quantification_a_single-center_retrospective_observational_pilot_study_docx/29579630
下载链接
链接失效反馈
官方服务:
资源简介:
BackgroundSepsis-induced disseminated intravascular coagulation (DIC) is associated with critical conditions and linked to a high mortality rate. Anticoagulants such as recombinant human soluble thrombomodulin (rhTM) and antithrombin are used to treat sepsis-associated DIC; however, their efficacy remains controversial. Syndecan-1, a biomarker of endothelial glycocalyx injury, has been proposed as a potential indicator of sepsis severity and prognosis. This study aimed to investigate the association between serum syndecan-1 levels and recovery from sepsis-associated DIC in patients treated with anticoagulants. MethodsA retrospective observational study was conducted at Gifu University Hospital. Patients aged ≥ 20 years with sepsis-associated DIC treated with anticoagulants (rhTM and antithrombin III) for ≥2 days were included. Serum syndecan-1 levels were measured at baseline, during treatment, and at 2 days after therapy. The relationship between syndecan-1 levels and recovery from DIC, assessed using the Japanese Association for Acute Medicine (JAAM)-2 and JAAM-DIC criteria, was analyzed. ResultsThirteen patients were included. Serum syndecan-1 levels peaked at the start of anticoagulation therapy, decreased during treatment, and increased after cessation of therapy. Recovery from DIC was associated with lower post-treatment syndecan-1 levels (p < 0.05). In patients who did not recover, syndecan-1 levels increased by more than 30%, correlating with poor outcomes, including mortality. ConclusionSyndecan-1 is a potential marker for monitoring endothelial injury and recovery from sepsis-associated DIC. Extended anticoagulant therapy may improve outcomes by reducing endothelial damage and potentially enhancing recovery from DIC in patients with sepsis. Further large-scale studies are required to confirm these findings.
创建时间:
2025-07-16
二维码
社区交流群
二维码
科研交流群
商业服务